FREQUENCY AND PREDICTIVE FACTORS OF COLECTOMYAND COLOPROCTECTOMY IN ULCERATIVE COLITIS

##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Vol. 87 No. 2 (2009): Issue Feb 2009

##plugins.themes.academic_pro.article.main##

Sami Karoui
Department of Gastroenterology A
Meriem Serghini
Department of Gastroenterology A
Mona Chaieb
Service de Gastro-entérologie A. Hôpital la Rabta. Tunis Service de Gastro-entérologie. Hôpital Charles Nicolle. Tunis.
Taieb Jomni
Service de Gastro-entérologie A. Hôpital la Rabta. Tunis
Lamia Kallel
Department of Gastroenterology A
Monia Fekih
Service de Gastro-entérologie A. Hôpital la Rabta. Tunis
Samira Matri
Department of Gastroenterology A.
Jalel Boubaker
Department of Gastroenterology A
Azza Filali
Department of Gastroenterology A.

Abstract

Aims : To determine the frequency and the predictive factors of colectomy and coloproctectomy in patients with ulcerative colitis.
Methods: We conducted an 11-year retrospective study based on hospitalized ulcerative colitis patients followed up for more than 6 months.
Results: From 1995 to 2005, 115 patients were included (50 men, 65 women, mean age: 38.4 years). Mean duration of follow-up was 39.2 months (6 – 145). Colectomy was performed in 20 patients (17%), with an actuarial risk of 16% at 5 years and 35% at 10 years. Proctocolectomy with ileoanal anastomosis was performed in 16 cases and total colectomy with ileorectal anastomosis in 4 cases. In univariate analysis, factors associated with an increased risk of colectomy were pancolitic location (p=0.02), acute severe colitis (p<0.0001), treatment by intravenous corticosteroids (p<0.0001) and intravenous cyclosporine (p=0.001). In multivariate analysis, acute severe colitis was the only independent factor associated with colectomy (p = 0.04 OR[CI95%] :6.66[1.04 - 50]). In patients with distal location, the independent factor associated with colectomy was colonic extension during follow up (p = 0.04 OR[CI95%] :7.69[1.07 - 50]). In patients with pancolitic location, risk of colectomy was associated with acute severe colitis (p = 0.01 OR[CI95%] :9.09[1.58 - 50]) and years of hospitalization from 1995 to 1999 (p = 0.02
OR[CI95%] :7.14[1.35 – 44]).
Conclusion: Although the diffusion of treatment by intravenous cyclosporin, surgery is frequently performed in our ulcerative colitis patients, specially in case of acute severe colitis. Evaluation of colonic extension during the follow-up is associated with an important prognostic impact.

Keywords:

Ulcerative colitis, Colectomy

##plugins.themes.academic_pro.article.details##

References

  1. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002 ;359:331-340.
  2. Mehdi A, Baccouche A, Skandrani K et al. Epidémiologie des maladies inflammatoires cryptogénétiques de l'intestin dans le centre-est Tunisien. Maghreb Médical 1997 ;314 :47-52.
  3. Collins P, Rhodes J. Ulcerative colitis : diagnosis and management. BMJ 2006 ;333:340-343.
  4. Elton C, Makin G, Hitos K, Cohen CR. Mortality, morbidity and functionel outcome after ileorectal anastomosis. Br J Surg 2003;90:59-65.
  5. Durai D, Hawthorne AB. How and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005;22:907-916.
  6. Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006;35:821-836.
  7. Moskovitz DN, Van Assche G, Maenhout B et al. Incidence of colectomy during long-term follow up after cyclosporin-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:760-765.
  8. Truelove SC, Witts LS. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955;1:1041-1048.
  9. Carbonnel F, Lavergne A, Lemann M et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994;39:1550-1557.
  10. Cohen JL, Strong SA, Hyman NH et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 2005;48:1997-2009.
  11. Caprilli R, Viscido A, Latella G. Current management of severe ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2007;4:92-101.
  12. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2006;5:103-110.
  13. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006;19:CD000279.
  14. Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J Clin Gastroenterol 2006;40:669-677.
  15. Michelassi F, Lee J, Rubin M et al. Long-term fucntionnal results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg 2003;238:433-441.
  16. Lepisto A, Jarvinen HJ. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. Scand J Surg 2005;94:40-42.
  17. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis : an epidemiologic study. Gut 1990;31:329-333.
  18. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long term follow up of 1116 patients. Dis Dis Sci 1993;38:1137-1146.
  19. Hoie O, Wolters FL, Riis L et al. Low colectomy rates in ulcerative colitis in an unselected european cohort followed for 10 years. Gastroenterology 2007;132:507-513.
  20. Nguyen GC, Laveist TA, Gearhart S, Bayless TM, Brant SR. Racial and geographic variations in colectomy rates among hospitalized ulcerative colitis patients. Clin Gastroenterol Hepatol 2006;4:1507-1513.
  21. Henriksen M, Jahnsen J, Lygren I et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006;12:543-550.
  22. Kuriyama M, Kato J, Fujimoto T et al. Risk factors and indications for colectomy in ulcerative colitis patients are different according to patient's clinical background. Dis Colon Rectum 2006;49:1307-1315.
  23. Loftus EV Jr. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am 2006;35:517-531.
  24. Pica R, Paoluzi OA, Iacopini F et al. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis 2004;10:731-736.
  25. Ghirardi M, Nascimbeni R, Mariani PP, Di Fabio F, Salerni B. Course and natural history of idiopathic ulcerative proctitis in adults. Ann Ital Chir 2002;73:155-158.
  26. Meucci G, Vecchi M, Astegiano M et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Am J Gastroenterol 2000;95:469-473.